BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 20812013)

  • 1. [cFLIP diminishes CD95-induced apoptosis of CD30-stimulated cutaneous anaplastic large T cell lymphoma (cALCL) cells].
    Hirsch B; Braun FK; Al-Yacoub N; Assaf C; Kadin ME; Sterry W; Eberle J; Dürkop H
    Pathologe; 2010 Oct; 31 Suppl 2():193-8. PubMed ID: 20812013
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Resistance of cutaneous anaplastic large-cell lymphoma cells to apoptosis by death ligands is enhanced by CD30-mediated overexpression of c-FLIP.
    Braun FK; Hirsch B; Al-Yacoub N; Dürkop H; Assaf C; Kadin ME; Sterry W; Eberle J
    J Invest Dermatol; 2010 Mar; 130(3):826-40. PubMed ID: 19890350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of p38 mitogen-activated protein kinase unmasks a CD30-triggered apoptotic pathway in anaplastic large cell lymphoma cells.
    Krysov SV; Rowley TF; Al-Shamkhani A
    Mol Cancer Ther; 2007 Feb; 6(2):703-11. PubMed ID: 17308066
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunohistochemical analysis of CD30-positive lymphoproliferative disorders for expression of CD95 and CD95L.
    Sigel JE; Hsi ED
    Mod Pathol; 2000 Apr; 13(4):446-51. PubMed ID: 10786813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential expression and function of A20 and TRAF1 in Hodgkin lymphoma and anaplastic large cell lymphoma and their induction by CD30 stimulation.
    Dürkop H; Hirsch B; Hahn C; Foss HD; Stein H
    J Pathol; 2003 Jun; 200(2):229-39. PubMed ID: 12754742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential molecular programs of cutaneous anaplastic large cell lymphoma and CD30-positive transformed mycosis fungoides.
    Lai P; Liu F; Liu X; Sun J; Wang Y
    Front Immunol; 2023; 14():1270365. PubMed ID: 37790936
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Galectin-1-mediated cell death is increased by CD30-induced signaling in anaplastic large cell lymphoma cells but not in Hodgkin lymphoma cells.
    Suzuki O; Hirsch B; Abe M; Dürkop H; Stein H
    Lab Invest; 2012 Feb; 92(2):191-9. PubMed ID: 21986812
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FAS death domain deletions and cellular FADD-like interleukin 1beta converting enzyme inhibitory protein (long) overexpression: alternative mechanisms for deregulating the extrinsic apoptotic pathway in diffuse large B-cell lymphoma subtypes.
    Takahashi H; Feuerhake F; Kutok JL; Monti S; Dal Cin P; Neuberg D; Aster JC; Shipp MA
    Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3265-71. PubMed ID: 16740746
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Death receptor apoptosis signaling mediated by FADD in CD30-positive lymphoproliferative disorders involving the skin.
    Clarke LE; Bayerl MG; Bruggeman RD; Mauger D; Ioffreda MD; Abou-Elella A; Helm KF
    Am J Surg Pathol; 2005 Apr; 29(4):452-9. PubMed ID: 15767797
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD30 Downregulation, MMAE Resistance, and MDR1 Upregulation Are All Associated with Resistance to Brentuximab Vedotin.
    Chen R; Hou J; Newman E; Kim Y; Donohue C; Liu X; Thomas SH; Forman SJ; Kane SE
    Mol Cancer Ther; 2015 Jun; 14(6):1376-84. PubMed ID: 25840583
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD30-induced up-regulation of the inhibitor of apoptosis genes cIAP1 and cIAP2 in anaplastic large cell lymphoma cells.
    Hübinger G; Schneider C; Stöhr D; Ruff H; Kirchner D; Schwänen C; Schmid M; Bergmann L; Müller E
    Exp Hematol; 2004 Apr; 32(4):382-9. PubMed ID: 15050749
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distinct motifs in the intracellular domain of human CD30 differentially activate canonical and alternative transcription factor NF-κB signaling.
    Buchan SL; Al-Shamkhani A
    PLoS One; 2012; 7(9):e45244. PubMed ID: 23028875
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BIN1 tumor suppressor regulates Fas/Fas ligand-mediated apoptosis through c-FLIP in cutaneous T-cell lymphoma.
    Esmailzadeh S; Huang Y; Su MW; Zhou Y; Jiang X
    Leukemia; 2015 Jun; 29(6):1402-13. PubMed ID: 25578476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD30-induced signaling is absent in Hodgkin's cells but present in anaplastic large cell lymphoma cells.
    Hirsch B; Hummel M; Bentink S; Fouladi F; Spang R; Zollinger R; Stein H; Dürkop H
    Am J Pathol; 2008 Feb; 172(2):510-20. PubMed ID: 18187570
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High level of cFLIP correlates with resistance to death receptor-induced apoptosis in bladder carcinoma cells.
    Jönsson G; Paulie S; Grandien A
    Anticancer Res; 2003; 23(2B):1213-8. PubMed ID: 12820373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fas/CD95 down-regulation in lymphoma cells through acquired alkyllysophospholipid resistance: partial role of associated sphingomyelin deficiency.
    van Blitterswijk WJ; Klarenbeek JB; van der Luit AH; Alderliesten MC; van Lummel M; Verheij M
    Biochem J; 2009 Dec; 425(1):225-34. PubMed ID: 19824885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spectrum of CD30+ lymphoid proliferations in the eyelid lymphomatoid papulosis, cutaneous anaplastic large cell lymphoma, and anaplastic large cell lymphoma.
    Sanka RK; Eagle RC; Wojno TH; Neufeld KR; Grossniklaus HE
    Ophthalmology; 2010 Feb; 117(2):343-51. PubMed ID: 19969358
    [TBL] [Abstract][Full Text] [Related]  

  • 18. mRNA expression patterns indicate CD30 mediated activation of different apoptosis pathways in anaplastic large cell lymphoma but not in Hodgkin's lymphoma.
    Staber PB; Noehammer C; Dürkop H; Schauer S; Kenner L; Linkesch W; Hoefler G
    Leuk Res; 2006 Mar; 30(3):343-8. PubMed ID: 16198418
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SATB1 Defines a Subtype of Cutaneous CD30
    Sun J; Yi S; Qiu L; Fu W; Wang A; Liu F; Wang L; Wang T; Chen H; Wang L; Kadin ME; Tu P; Wang Y
    J Invest Dermatol; 2018 Aug; 138(8):1795-1804. PubMed ID: 29510190
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Variable loss of CD30 expression by immunohistochemistry in recurrent cutaneous CD30+ lymphoid neoplasms treated with brentuximab vedotin.
    Goyal A; Patel S; Goyal K; Morgan EA; Foreman RK
    J Cutan Pathol; 2019 Nov; 46(11):823-829. PubMed ID: 31286556
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.